Close Menu

BMS

In the study, called TAPUR, ASCO will give cancer patients who are out of treatment options off-label drugs based on their genomic data and record their outcomes in a registry.

Researchers explored the predictive value of using mismatch repair deficiency and PD-L1 expression to assess which cancer patients are likely to respond to anti-PD-1 treatments.

A blueprint that four drugmakers released during the meeting represents an initial effort to explore the analytical differences between CDx for drugs in the same class.

The companies are collaborating on a companion diagnostic intended to identify best responders to the PD-1 inhibitor.

NEW YORK (GenomeWeb) — Danaher's Leica Biosystems said today that it has made a deal with Bristol-Myers Squibb to collaborate in developing companion diagnostics to predict which patients will respond to BMS-developed targeted therapies.

Can drugmakers be held liable for failing to aggressively warn consumers that patients with certain genetic markers will not respond or will have limited response to their drugs beyond just mentioning this information in drug labeling?

NEW YORK (GenomeWeb News) – IncellDx and Bristol-Myers Squibb have signed an agreement to develop a molecular test that may eventually be used as a companion diagnostic to identify best responders to an investigational drug in BMS's pipeline.

After appointing a new CEO this summer, SQI Diagnostics is continuing its focus on services to pharmaceutical partners in providing custom multiplex immunogenicity panels, with its pipeline of in vitro diagnostics assays as a second priority, the company said this week.

Pages

Researchers have sequenced the genome of the depth-dwelling giant squid.

Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.

 

Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.

In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.